Updated:
AbCellera Biologics
Carl Hansen's AbCellera combines microfluidic antibody screening with an internal drug pipeline, partnering with Eli Lilly and Moderna from its Vancouver...
AbCellera Biologics
Carl Hansen co-founded AbCellera in 2012 alongside colleagues from the University of British Columbia, commercializing a high-throughput microfluidic platform that screens millions of immune cells to identify functional antibodies. The technology attracted early collaborators, including DARPA and the Gates Foundation, but the firm remained relatively quiet until 2020, when its partnership with Eli Lilly yielded bamlanivimab, one of the first COVID-19 neutralizing antibodies to reach patients. That program moved from sample collection to clinical material in roughly 90 days, establishing AbCellera's reputation for speed in emergency response. AbCellera's business model spans partnered discovery, where it earns milestones and royalties, and an internal pipeline of wholly owned antibody programs. The platform screens single B cells from immunized transgenic mice or human donors, coupling microfluidics with computational immunology to isolate leads against high-value targets in oncology, inflammation, and infectious disease. Partners include Gilead, Regeneron, and Moderna, each tapping AbCellera's engine for programs where conventional hybridoma or phage display approaches have stalled. The firm has historically charged upfront fees and retained downstream economics, a structure closer to a biotech co-developer than a CRO. Public since 2022 on the Nasdaq under ticker ABCL, AbCellera posted approximately $485 million in cumulative revenue through its first three years as a public company, largely driven by milestone payments from its COVID-era partnerships. The firm employs over 600 people across its Vancouver headquarters, with additional offices in Wuxi, China and Amsterdam, but has also disclosed plans for a major purpose-built GMP manufacturing facility in Vancouver to support its own pipeline candidates. In early 2024, AbCellera announced a restructuring that deprioritized early-stage drug discovery services to focus capital and headcount on advancing its internal oncology and inflammatory disease programs toward the clinic. AbCellera operates as a publicly traded biotech, yet its revenue model still depends heavily on a handful of large-partner milestone payments—an architecture that distinguishes it from traditional asset-heavy drug developers. Its dual-identity as both a partner's discovery engine and an aspiring therapeutics company creates a structural tension where partnered programs compete for resources with internal pipeline assets. Succession and governance remain concentrated around Carl Hansen, who holds significant voting control through Class B shares, a structure common among founder-led biotechs but one that concentrates strategic risk.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
Vancouver, BC, Canada
Additional offices
Wuxi, China · Amsterdam, Netherlands
Principals
Carl Hansen
Founder and CEO
Sector focus
Frequently asked questions
Is AbCellera a CRO or a biotechnology company?
AbCellera operates as both, but is increasingly emphasizing its own internal drug pipeline. The firm historically earned revenue through partnered discovery programs—charging upfront fees and receiving milestone payments—while retaining rights to wholly owned antibody programs. In early 2024, the company announced a restructuring to focus capital on advancing its oncology and inflammatory disease candidates, signaling a shift toward a biotech identity that still maintains active partnerships with companies like Regeneron and Moderna.
What is AbCellera's core technology?
AbCellera's platform combines microfluidic screening of millions of individual B cells from immunized sources or human donors with machine-learning algorithms to identify rare antibodies with desired functional properties. The approach bypasses traditional hybridoma or phage display bottlenecks, enabling candidate selection in weeks rather than months. The underlying technology originated from Carl Hansen's academic work at the University of British Columbia.
Did AbCellera's COVID-19 antibody program create an ongoing revenue stream?
Bamlanivimab, developed with Eli Lilly, generated substantial milestone revenue for AbCellera during 2020-2022, but those payments have since declined as COVID-19 variant resistance and updated therapeutic strategies reduced commercial utility. The firm's subsequent revenue diversified through new partnerships, including programs with Moderna and Gilead, though no single program has matched the scale of its initial pandemic-era milestone stream.
What investment stages does AbCellera target for its own development pipeline?
AbCellera targets the preclinical-to-IND (Investigational New Drug) stage for its internal programs, aiming to advance antibody candidates through discovery and manufacturing readiness before considering external partnerships or Phase I clinical trials. The firm's planned GMP manufacturing facility in Vancouver reflects an intent to retain operational control through early clinical material production.
How does AbCellera's governance structure concentrate decision-making?
Carl Hansen controls a majority of voting power through AbCellera's dual-class share structure, where Class B shares carry enhanced voting rights. This structure is relatively common among founder-led publicly traded biotechs but places significant strategic concentration in a single individual, including decisions on resource allocation between partnered revenue programs and internal pipeline investments.
Who runs investment and strategic decisions at AbCellera?
Carl Hansen, as Founder and CEO, leads AbCellera's strategic direction, including capital allocation decisions between partnered discovery programs, internal pipeline development, and infrastructure investments such as the planned Vancouver GMP facility. The firm's public-company structure includes an independent board, but Hansen's Class B voting shares give him effective control over major strategic pivots.
Which sectors does AbCellera explicitly avoid?
AbCellera does not invest in small-molecule discovery or non-antibody biologics such as bispecific T-cell engagers. The platform is purpose-built for monoclonal antibody discovery against protein targets, and the firm has publicly stated it remains focused on inflammatory disease, oncology, and infectious disease—avoiding central nervous system and rare metabolic disorders where antibody approaches face limited blood-brain barrier access.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: